CIK 0001764013 · Large accelerated filer
Immunovant, Inc.
Sign in to watch- Ticker
- IMVT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832771572
- Phone
- 917-410-3120
- Business address
- 1000 PARK FORTY PLAZA, DURHAM, NC, 27713
- Former names
- Health Sciences Acquisitions Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,030,805
- in 10 filings, $173K under 10b5-1 plans
Net −$1,030,805. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-26 | Van Tuyl Christopher Chief Legal Officer | Sale | −14,982 | $38.19 | $572K | 183,439 |
| 2026-06-26 | Van Tuyl Christopher Chief Legal Officer | Sale | −2,842 | $38.96 | $111K | 180,597 |
| 2026-06-26 | Van Tuyl Christopher Chief Legal Officer | Option exercise · Stock Option (right to buy) | −17,824 | 53,707 | ||
| 2026-06-26 | Girao Tiago Chief Financial Officer | Option exercise | +10,000 | $15.90 | $159K | 257,596 |
| 2026-06-26 | Girao Tiago Chief Financial Officer | Sale | −10,000 | $38.46 | $385K | 247,596 |
| 2026-06-26 | Girao Tiago Chief Financial Officer | Option exercise · Stock Option (right to buy) | −10,000 | 283,505 | ||
| 2026-06-26 | Pande Atul Director | Option exercise 10b5-1 | +1,500 | $8.43 | $13K | 118,231 |
| 2026-06-26 | Pande Atul Director | Sale 10b5-1 | −1,500 | $38.01 | $57K | 116,731 |
| 2026-06-26 | Pande Atul Director | Option exercise · Stock Option (right to buy) 10b5-1 | −1,500 | 68,181 | ||
| 2026-06-18 | Van Tuyl Christopher Chief Legal Officer | Sale | −2,634 | $35.39 | $93K | 180,597 |
| 2026-06-15 | Pande Atul Director | Option exercise 10b5-1 | +1,500 | $8.43 | $13K | 118,231 |
| 2026-06-15 | Pande Atul Director | Sale 10b5-1 | −1,500 | $34.02 | $51K | 116,731 |
| 2026-06-15 | Pande Atul Director | Option exercise · Stock Option (right to buy) 10b5-1 | −1,500 | 69,681 | ||
| 2026-05-28 | Fromkin Andrew J. Director | Option exercise | +31,668 | $4.99 | $158K | 131,400 |
| 2026-05-28 | Fromkin Andrew J. Director | Option exercise | +71,492 | $7.94 | $568K | 202,892 |
| 2026-05-28 | Fromkin Andrew J. Director | Option exercise | +77,181 | $8.43 | $651K | 280,073 |
| 2026-05-28 | Fromkin Andrew J. Director | Option exercise | +16,260 | $14.70 | $239K | 296,333 |
| 2026-05-28 | Fromkin Andrew J. Director | Sale | −11,483 | $32.64 | $375K | 284,850 |
| 2026-05-28 | Fromkin Andrew J. Director | Sale | −210,468 | $33.56 | $7.1M | 74,382 |
| 2026-05-28 | Fromkin Andrew J. Director | Option exercise · Stock Option (right to buy) | −31,668 | 0 |
Page 3 of 10 · 191 trades